{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SARS-CoV-2+mRNA+Dose+1&page=3",
    "query": {
      "intervention": "SARS-CoV-2 mRNA Dose 1",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 60,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SARS-CoV-2+mRNA+Dose+1&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SARS-CoV-2+mRNA+Dose+1&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T10:33:50.146Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07808697",
      "title": "A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "SARS-CoV-2"
      ],
      "interventions": [
        {
          "name": "mRNA-1283",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1273",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "6 Months to 11 Years"
      },
      "enrollment_count": 300,
      "start_date": "2026-09-01",
      "completion_date": "2029-08-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-10-23T10:33:50.146Z",
      "location_count": 13,
      "location_summary": "Ontario, California • Miami, Florida • Miami Lakes, Florida + 9 more",
      "locations": [
        {
          "city": "Ontario",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        },
        {
          "city": "Tamarac",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07808697"
    },
    {
      "nct_id": "NCT05330975",
      "title": "A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Respiratory Syncytial Virus"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1345",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Afluria® Quadrivalent",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1273.214",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 3317,
      "start_date": "2022-04-01",
      "completion_date": "2024-11-08",
      "has_results": true,
      "last_update_posted_date": "2025-12-30",
      "last_synced_at": "2026-10-23T10:33:50.146Z",
      "location_count": 62,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Garden Grove, California + 51 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05330975"
    },
    {
      "nct_id": "NCT05260437",
      "title": "Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COVID-19",
        "SARS-CoV-2"
      ],
      "interventions": [
        {
          "name": "CV2CoV (2 µg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV2CoV (4 µg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV2CoV (8 µg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV2CoV (12 µg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV2CoV (16 µg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV2CoV (20 µg)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 99,
      "start_date": "2022-03-24",
      "completion_date": "2023-03-07",
      "has_results": true,
      "last_update_posted_date": "2024-08-12",
      "last_synced_at": "2026-10-23T10:33:50.146Z",
      "location_count": 24,
      "location_summary": "Aurora, Colorado • Hallandale, Florida • Lakeland, Florida + 11 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Hallandale",
          "state": "Florida"
        },
        {
          "city": "Hallandale",
          "state": "Florida"
        },
        {
          "city": "Lakeland",
          "state": "Florida"
        },
        {
          "city": "Lakeland",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05260437"
    },
    {
      "nct_id": "NCT05875701",
      "title": "Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "NVX-CoV2373",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SARS-CoV-2 rS antigen/Matrix-M Adjuvant",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novavax",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 147,
      "start_date": "2023-03-28",
      "completion_date": "2023-11-11",
      "has_results": true,
      "last_update_posted_date": "2025-06-26",
      "last_synced_at": "2026-10-23T10:33:50.146Z",
      "location_count": 5,
      "location_summary": "Austin, Texas • Fort Worth, Texas • Plano, Texas + 1 more",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        },
        {
          "city": "Plano",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05875701"
    },
    {
      "nct_id": "NCT05972993",
      "title": "A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "mRNA-CR-04 vaccine 10μg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-CR-04 vaccine 30μg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-CR-04 vaccine 100μg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "mRNA-CR-04 vaccine 3μg",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 114,
      "start_date": "2023-08-07",
      "completion_date": "2024-10-14",
      "has_results": true,
      "last_update_posted_date": "2025-05-28",
      "last_synced_at": "2026-10-23T10:33:50.146Z",
      "location_count": 4,
      "location_summary": "San Diego, California • Melbourne, Florida • Peoria, Illinois + 1 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05972993"
    },
    {
      "nct_id": "NCT06189053",
      "title": "A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Myocarditis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1500,
      "start_date": "2022-04-30",
      "completion_date": "2028-10-31",
      "has_results": false,
      "last_update_posted_date": "2025-08-01",
      "last_synced_at": "2026-10-23T10:33:50.146Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06189053"
    },
    {
      "nct_id": "NCT05137236",
      "title": "A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "SARS-CoV-2"
      ],
      "interventions": [
        {
          "name": "mRNA-1283",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1283.211",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1273",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1283.529",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 540,
      "start_date": "2021-12-06",
      "completion_date": "2023-03-23",
      "has_results": true,
      "last_update_posted_date": "2025-07-17",
      "last_synced_at": "2026-10-23T10:33:50.146Z",
      "location_count": 17,
      "location_summary": "Phoenix, Arizona • Hollywood, Florida • Sunrise, Florida + 13 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Sunrise",
          "state": "Florida"
        },
        {
          "city": "Chamblee",
          "state": "Georgia"
        },
        {
          "city": "Metairie",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05137236"
    },
    {
      "nct_id": "NCT05585632",
      "title": "A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "SARS-CoV-2",
        "Influenza",
        "RSV"
      ],
      "interventions": [
        {
          "name": "mRNA-1010",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1345",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1273.214",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1045",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1230",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "50 Years to 75 Years"
      },
      "enrollment_count": 392,
      "start_date": "2022-10-14",
      "completion_date": "2024-02-28",
      "has_results": false,
      "last_update_posted_date": "2024-03-08",
      "last_synced_at": "2026-10-23T10:33:50.146Z",
      "location_count": 14,
      "location_summary": "DeLand, Florida • Hollywood, Florida • St. Petersburg, Florida + 11 more",
      "locations": [
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Columbus",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05585632"
    },
    {
      "nct_id": "NCT06441955",
      "title": "Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "COVID-19, Long Haul"
      ],
      "interventions": [
        {
          "name": "Ritonavir-Boosted Nirmatrelvir (Paxlovid)",
          "type": "DRUG"
        },
        {
          "name": "Physiological Evaluation",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Moderna COVID-19 Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Biopsychological",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Behavioral (e.g., Psychotherapy, Lifestyle Counseling)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Genetic (including gene transfer, stem cell and recombinant DNA)",
          "type": "GENETIC"
        },
        {
          "name": "Multidisciplinary approach",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST",
        "BIOLOGICAL",
        "BEHAVIORAL",
        "GENETIC",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Well- Konnect Healthcare Services and Research Firm",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 100,
      "start_date": "2024-03-01",
      "completion_date": "2030-09-30",
      "has_results": false,
      "last_update_posted_date": "2024-11-27",
      "last_synced_at": "2026-10-23T10:33:50.146Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06441955"
    },
    {
      "nct_id": "NCT05367843",
      "title": "A Study Assessing the Safety, Tolerability, Immunogenicity of COVID-19 Vaccine Candidate PRIME-2-CoV_Beta, Orf Virus Expressing SARS-CoV_2 Spike and Nucleocapsid Proteins",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "SARS-CoV-2 Infection"
      ],
      "interventions": [
        {
          "name": "PRIME-2-CoV_Beta",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Speransa Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 103,
      "start_date": "2022-06-20",
      "completion_date": "2023-11-08",
      "has_results": false,
      "last_update_posted_date": "2024-02-09",
      "last_synced_at": "2026-10-23T10:33:50.146Z",
      "location_count": 5,
      "location_summary": "Florida City, Florida • Chicago, Illinois • Kansas City, Missouri + 2 more",
      "locations": [
        {
          "city": "Florida City",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Fayetteville",
          "state": "North Carolina"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05367843"
    }
  ]
}